recombinant human mutated angiopoietin-like 4

Recombinant human mutated angiopoietin-like 4 (also known as protein 8520) is an engineered, first-in-class biological drug candidate designed for the treatment and reversal of chronic kidney disease (CKD). Developed by researchers at the University of Alabama at Birmingham and Rush University Medical Center, this therapeutic protein is a mutated version of human angiopoietin-like 4 (ANGPTL4). It is specifically modified at normal cleavage sites to increase its half-life, and at sites important for its interaction with lipoprotein lipase (LPL) to avoid inducing hypertriglyceridemia. The drug acts by binding to integrins β1 and ε5 (specifically podocyte α3β1, glomerular endothelial αvβ5, and interstitial capillary endothelial α1β1) to exert potent anti-apoptotic activity, keeping capillaries open for repair and promoting tissue repair to reverse established CKD.

Other names

protein 8520protein8520protein-8520recombinant human mutated ANGPTL4recombinant mutated human ANGPTL4recombinant mutated human angiopoietin-like 4